logo-loader
RNS
viewEvgen Pharma PLC

Update on extended-use phase of STEM trial

/**/ h2{margin-right:0cm;margin-left:0cm;font-size:18.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .ad{size:595.0pt 842.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ad{}p.bp{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; margin-right: 8.4pt; text-align: center}span.bn{font-size:11.0pt;color:black}p.bq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif"; margin-right: 8.4pt; text-align: center}p.br{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; margin-left: 18.0pt; text-align: center}span.bk{font-size:11.0pt;font-family:"Calibri Light","sans-serif"; color:black}p.bs{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";}p.bt{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify} span.bh{font-size:11.0pt; color:black}span.bg{font-size:11.0pt}p.bu{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold}p.bv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";padding-top:1.0pt}table.bw{margin-left:-5.4pt;border-collapse:collapse}td.ax{width:201.6pt;padding:0cm 5.4pt 0cm 5.4pt}p.bx{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;vertical-align: baseline;padding-top:1.0pt;padding-bottom:1.0pt;border-bottom:.5pt solid windowtext}span.by{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.bz{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.ca{font-size: 11.0pt;font-family:"Calibri","sans-serif"} span.cb{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.cc{font-size:11.0pt;font-family:"Arial","sans-serif"}td.at{width:227.3pt;padding:0cm 5.4pt 0cm 5.4pt}p.cd{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; padding-top: 1.0pt; text-align: right; vertical-align: baseline}span.ce{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-div: italic}span.cf{font-size:11.0pt; font-family:"Calibri","sans-serif"}span.cg{font-size: 11.0pt;font-family:"Calibri","sans-serif"}p.ch{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";padding-top:1.0pt;padding-bottom:1.0pt;border-bottom: .5pt solid windowtext}span.ci{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cj{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";padding-top: 1.0pt; text-align: right} span.ar{font-size:11.0pt;color:black;background:white}td.ap{width:231.95pt;padding:0cm 5.4pt 0cm 5.4pt}td.ao{width:196.95pt;padding:0cm 5.4pt 0cm 5.4pt}span.ck{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.cl{font-size:11.0pt;font-family: "Calibri","sans-serif"}span.cm{font-size:11.0pt;color:black}span.cn{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}td.al{border:none}p.co{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:.75pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify;vertical-align:baseline}span.cp{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold} span.cq{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.cr{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.cs{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.ct{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.ag{font-size:9.0pt;font-family:"quot","serif"}p.cu{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:8.25pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify; vertical-align:baseline}span.cv{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black} /**/
RNS Number : 1803N
Evgen Pharma PLC
23 September 2019
 

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

 

Update on extended-use phase of STEM clinical trial

 

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that five patients who participated in the STEM trial ("STEM") received SFX-01 treatment for over one year, with two of these five patients continuing to be treated with SFX-01. For these five patients, SFX-01 halted their previously progressive tumour growth for the full six month period of the trial and for at least a further six months of extended use on compassionate grounds. Of the two patients continuing to be treated with SFX-01, one has now reached 438 days of dosing, and the other, 476 days; the latter exceeding the previous best of 448 days. 

 

All patients entering STEM had ER+ metastatic (Stage 4) breast cancer and had confirmed progressive disease at the point of entry into the study (i.e. their tumour(s) had grown more than 20% since their last scan) and thus become resistant to their current and all prior treatments. SFX-01 was then administered in addition to the current failing therapy to investigate whether it was possible, in this advanced stage of disease, to elicit a clinical benefit by halting growth or shrinking the tumours(s).

 

As announced on 25 March 2019, the trial met both primary endpoints with approximately 25% of patients demonstrating clinical benefit for the full six month duration of the trial. Patients that continued to have a benefit at six months were able to continue on SFX-01 in an extension phase.

 

The news of this sustained response to SFX-01, comes just days before the Company is due to present the STEM results via a scientific poster at ESMO (European Society for Medical Oncology) in Barcelona on 29 September. A link to the poster will be announced shortly after its presentation.

 

Steve Franklin, CEO of Evgen Pharma, commented: "We are delighted that these patients continue to benefit from SFX-01 after their participation in the STEM trial. This patient group has failed on all previous therapies and have very few options remaining. We could not have expected to see this kind of enduring benefit in such late stage disease and so we continue to plan with heightened confidence the on-going development of SFX-01 in ER+ metastatic breast cancer - targeting the earlier stages of the disease before resistance to all endocrine therapies is established. In this earlier part of the treatment path, one would expect SFX-01 to have even more impact where its role will be to significantly extend the utility of endocrine therapies without increasing the side effect burden."

 

Enquiries:

 

Evgen Pharma plc www.evgen.com 

via Walbrook 

Dr Stephen Franklin, CEO 

 

Richard Moulson, CFO 

 

 

 

finnCap www.finncap.com 

+44 (0) 20 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance) 

 

Alice Lane, Manasa Patil (ECM) 

 


 

WG Partners LLP 

+44 (0) 20 3705 9330 

Nigel Barnes / Claes Spång  

 


 

Walbrook PR 

+44 (0)20 7933 87870 or [email protected]

Paul McManus / Anna Dunphy 

+44 (0)7980 541 893 / +44 (0)7876 741 001 

 

 

About Evgen Pharma plc 

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.  

 

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

 

For further information, please visit: www.evgen.com 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RESPGUMUBUPBGAU

Quick facts: Evgen Pharma PLC

Price: 7.45

Market: AIM
Market Cap: £9.88 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE